Urethral Bulking Systems Market Scope
Involuntary loss of urine during a period of elevated abdominal pressure and in the absence of detrusor activity is known as stress urinary incontinence (SUI). Bulking drugs administered in the urethra are a relatively new but well-established therapeutic option for SUI. Understanding the demographics of SUI can aid in the selection of patients who will benefit from bulking agent therapy. In women, urethral thickening is normally performed under local anaesthetic, whereas men may require general or regional anaesthesia. After an injection, a local anaesthetic lets the person to get up to see if continence has been attained.
The Urethral Bulking Systems market study is segmented and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Urethral Bulking Systems market throughout the predicted period.
CR Bard (Becton, Dickinson and Company.) (United States), Merz Pharma GmbH & Co. KGaA (Germany), Cogentix Medical (Laborie, Inc.) (United States), Q-Med (Sweden), Ascentx Medical, Inc. (United States), Coloplast Corp (United States), Boston Scientific Corporation (United States) and AstraZeneca plc (United Kingdom) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Urethral Bulking Systems market by Type, Application and Region.
On the basis of geography, the market of Urethral Bulking Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 28th January, 2020 - Contura International A/S Received US FDA Approval for its Application for Bulkamid Urethral Bulking System - P170023. Bulkamid is a Thick, Lasting Gel Is Used for Treatment of Stress Urine Incontinence in Women Who Have Weak Pelvic Floor Muscles (Urethral Sphincter).
- Rising Geriatric Population
- Prevalence of Stress Urinary Incontinence (SUI)
- Growing Healthcare Awareness
- High Investment in Healthcare R&D
- Growing Medical Infrastructure Across Emerging Regions
- Fierce Competitive Pressure
Key Target AudienceUrethral Bulking Systems Manufactures, New Entrants and Investors, Urethral Bulking Systems Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Urethral Bulking Systems Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.